全文获取类型
收费全文 | 28032篇 |
免费 | 2003篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 759篇 |
妇产科学 | 797篇 |
基础医学 | 4330篇 |
口腔科学 | 139篇 |
临床医学 | 2481篇 |
内科学 | 7626篇 |
皮肤病学 | 278篇 |
神经病学 | 2166篇 |
特种医学 | 1097篇 |
外科学 | 4265篇 |
综合类 | 124篇 |
现状与发展 | 1篇 |
一般理论 | 45篇 |
预防医学 | 2168篇 |
眼科学 | 215篇 |
药学 | 1613篇 |
中国医学 | 16篇 |
肿瘤学 | 1867篇 |
出版年
2024年 | 16篇 |
2023年 | 733篇 |
2022年 | 998篇 |
2021年 | 1314篇 |
2020年 | 1205篇 |
2019年 | 791篇 |
2018年 | 962篇 |
2017年 | 934篇 |
2016年 | 877篇 |
2015年 | 969篇 |
2014年 | 1660篇 |
2013年 | 1523篇 |
2012年 | 1415篇 |
2011年 | 1450篇 |
2010年 | 1344篇 |
2009年 | 1359篇 |
2008年 | 1267篇 |
2007年 | 1181篇 |
2006年 | 1045篇 |
2005年 | 1041篇 |
2004年 | 1083篇 |
2003年 | 1014篇 |
2002年 | 1016篇 |
2001年 | 1106篇 |
2000年 | 961篇 |
1999年 | 882篇 |
1998年 | 425篇 |
1997年 | 259篇 |
1996年 | 192篇 |
1995年 | 151篇 |
1994年 | 110篇 |
1993年 | 95篇 |
1992年 | 125篇 |
1991年 | 96篇 |
1990年 | 88篇 |
1989年 | 71篇 |
1988年 | 46篇 |
1987年 | 35篇 |
1985年 | 31篇 |
1984年 | 24篇 |
1983年 | 20篇 |
1982年 | 21篇 |
1981年 | 24篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 12篇 |
1975年 | 14篇 |
1974年 | 12篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
34.
35.
《Journal of stroke and cerebrovascular diseases》2019,28(10):104277
Transcatheter Aortic Valve Implantation (TAVI) is an increasingly treatment modality for severe aortic stenosis, which is associated with a considerable peri-procedural risk of stroke. To date, the clinical safety and efficacy of Tissue plasminogen activator (tPA) and mechanical thrombectomy in stroke post-TAVI is not established. We describe 2 cases of patients with stroke after TAVI who received tPA therapy and mechanical thrombectomy. 相似文献
36.
《Survey of ophthalmology》2023,68(2):241-256
We quantitatively evaluated the efficacy of antitubercular therapy (ATT) in tubercular uveitis (TBU) patients. Main outcome measures include inflammation recurrence, inflammation reduction, complete resolution of inflammation, improved visual acuity (VA), ability to taper corticosteroids to < 10 mg/day without inflammatory progression, and use of adjunctive immunosuppressants while on ATT. This review is prospectively registered in PROSPERO (CRD42020206845). Forty-nine studies reporting data for 4,017 TBU patients were included. In comparative studies, the odds ratio (OR) of inflammatory recurrence was 0.33 (95%CI:0.19-0.60) for TBU patients treated with ATT±corticosteroid versus no ATT. For TBU patients treated with ATT±corticosteroid, the pooled absolute incidences of inflammatory recurrence, inflammatory reduction, complete resolution of inflammation, and visual acuity improvement were 13% (n=310/2,216; 95%CI:9-18), 81% (n=217/276; 95%CI: 62-95), 83% (n=1,167/1,812; 95%CI: 77-89), and 65% (n=347/542; 95%CI:51-78), respectively. Corticosteroids were tapered to <10 mg/day without inflammatory progression in 91% (n=326/395; 95%CI:78-99) of patients, 9% (n=121/1,376; 95%CI:6-13) of whom were administered concomitant immunosuppressive agents alongside ATT. We conclude that treatment of TBU with ATT±corticosteroid is associated with a high level of control or improvement of inflammation. More prospective studies with detailed reporting of ATT regimens, patient subgroups, and outcomes are required to better evaluate ATT effectiveness. 相似文献
37.
38.
39.
40.
《Seminars in oncology》2019,46(6):397-402
The opening session of Second International Colloquium on Cardio-Oncology addressed two areas of vital interest. The first reviewed new thoughts related to established agents. While anthracycline cardiotoxicity has been studied and reviewed extensively, ongoing research attempting to understand why it appears the mechanism(s) of toxicity differs from that of oncologic efficacy continue to evoke comment and intriguing speculation. Better understanding of the role of β-topoisomerase II in toxicity has advanced our understanding of the cascade of events that lead to heart failure. Additionally, the cardioprotective role of dexrazoxane fits well with our new understanding of how β-topoisomerase II works. Beyond the anthracyclines, new insight is providing us insight to better understand the impact on cardiac function seen with other agents including those targeting HER2 and several tyrosine-kinase inhibitors. Unlike the anthracyclines, these agents affect cardiac function in ways that are less direct, and therefore have different characteristics and should be thought of in alternate ways. This new knowledge regarding established agents furthers our understanding of the spectrum of cardiotoxicity and cardiac dysfunction in the cancer patient. The session also addressed cardiovascular toxicities of newer and established agents beyond myocardial dysfunction including effects on the vasculature. These agents cause changes that may be temporary or permanent, and that range from subclinical to life-threatening. The session ended with a discussion of the cardiac effects of immune checkpoint inhibitors. These agents can cause rare and sometimes fatal cardiac inflammation, for which long-term follow up may be required. 相似文献